Xencor (NASDAQ:XNCR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Xencor (NASDAQ:XNCR) from a hold rating to a buy rating in a research note issued to investors on Saturday,Wall Street Zen reports.

XNCR has been the topic of a number of other reports. Raymond James Financial raised their price objective on Xencor from $40.00 to $46.00 and gave the company a “strong-buy” rating in a report on Tuesday, September 1st. Bank of America upped their target price on Xencor from $20.00 to $26.00 and gave the stock a “neutral” rating in a research note on Monday, September 21st. Barclays set a $45.00 price target on shares of Xencor and gave the company an “overweight” rating in a research report on Monday, October 26th. Wedbush lifted their price target on shares of Xencor from $30.00 to $45.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 27th. Finally, Cantor Fitzgerald assumed coverage on shares of Xencor in a research note on Thursday, November 5th. They set an “overweight” rating and a $70.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $42.22.

Xencor Price Performance

XNCR opened at $38.59 on Friday. The business’s fifty day simple moving average is $26.42 and its 200 day simple moving average is $17.59. Xencor has a 52 week low of $10.38 and a 52 week high of $39.71.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.83. Xencor had a negative return on equity of 21.37% and a negative net margin of 58.79%. The firm had revenue of $116.52 million during the quarter, compared to analyst estimates of $63.00 million. During the same quarter in the previous year, the company posted ($0.08) earnings per share. The company’s revenue was up 453.3% compared to the same quarter last year. As a group, analysts expect that Xencor will post -2.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Xencor

Institutional investors and hedge funds have recently bought and sold shares of the stock. Integrated Wealth Concepts LLC bought a new position in shares of Xencor in the second quarter worth approximately $30,000. Bessemer Group Inc. raised its holdings in Xencor by 18.7% during the 3rd quarter. Bessemer Group Inc. now owns 1,791 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 282 shares during the last quarter. Allworth Financial LP bought a new stake in Xencor during the 2nd quarter valued at $55,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Xencor during the 3rd quarter valued at $95,000. Finally, GAMMA Investing LLC boosted its position in Xencor by 15.5% during the 3rd quarter. GAMMA Investing LLC now owns 4,269 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 572 shares during the period.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company’s XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target.

Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements.